PTLA News and Press, Portola Pharmaceuticals Inc. From 06/19/19

SOUTH SAN FRANCISCO, Calif. , June 19, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in patients with relapsed/refrac...

With the approval of Andexxa (Andexanet Alfa) came many headaches for those of us in the pharmacy world. The approval process was a bit odd and left us with many questions about safety, efficacy, cost, and post-administration anticoagulation. On top of that, it was made available to only selec...

– Excellent or Good Hemostasis Achieved in 79% of Evaluable Patients  with Spontaneous Intracranial Hemorrhage – – Data Featured in an Oral Presentation at the 5 th European Stroke Organisation Conference – SOUTH SAN FRANCISCO, Calif., May 22, 20...

Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma...

"Man is not what he thinks he is, he is what he hides .” ― André Malraux It has not been a good week for the market as trade tensions have escalated significantly between the U.S. and China. We have seen a slew of Q1 results this week even as equities have staged a cons...

Merck & Co ( MRK ) - The company announced results from the phase 2 study of V114 (15-valent pneumococcal conjugate vaccine) as compared to currently available 13-valent pneumococcal conjugate vaccine in healthy infants 6-12 weeks of age. The primary endpoint was met by demonstrating n...

Portola Pharmaceuticals, Inc. (PTLA) Q1 2019 Earnings Conference Call May 8, 2019 8:30 AM ET Company Participants Cara Miller – Vice President-Investor Relations and Corporate Communications Scott Garland – President and Chief Executive Officer Sheldon Koenig ȁ...

The following slide deck was published by Portola Pharmaceuticals, Inc. in conjunction with their 2019 Q1 earnings Read more ...

Inogen (NASDAQ: INGN )  -31%  on Q1 earnings . More news on: Inogen, Inc., Invitae Corporation, 2U, Inc., Stocks on the move, Read more ...

Portola Pharmaceuticals ( PTLA ) Q1 results : Revenues: $22.2M (+236.4%); Collaboration and license revenue: $1.8M (-70.0%). More news on: Portola Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...